Login to Your Account

Cash Up Front: $290

Amgen Takes Over Avidia: Deal Valued Up To $450M

By Randall Osborne

Monday, October 2, 2006
Avidia Inc.'s multiple-pathway, protein-chain platform charmed Amgen Inc. into a $290 million cash buyout that brings another $90 million in potential milestones for the privately held firm, which put its first drug candidate into the clinic this month. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription